Background: Current evidence suggests that membranetethered mucins could mediate corticosteroid efficacy, interacting with glucocorticoid receptor (GR) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Mucin 4 (MUC4)-tethered mucin is expressed in nasal polyp (NP) epithelial cells and upregulated under inflammatory conditions. Moreover, MUC4b has the capacity to interact with other intracellular proteins. We hypothesized that MUC4 modulates corticosteroid efficacy of patients with CRSwNP.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease characterized by the presence of edematous masses of inflamed mucosa, leading to nasal obstruction, secretion, loss of smell, headache/facial pain, and reduced quality of life. 1 CRSwNP is frequently associated with asthma and aspirin intolerance, and T H 2 cytokine expression and eosinophilic infiltration are characteristics. Overall, the cause and pathogenesis of CRSwNP remain a matter of debate, suggesting that a role for either fungi or bacteria in patients with CRSwNP might play a key role. 1 Nasal topical corticosteroids are the first-line treatment for CRSwNP, reducing polyp size, nasal symptoms, and the number of recurrences after polypectomy. 1 In case of a lack of clinical response, a 2-week course of systemic corticosteroids generally improves polyp size and nasal symptoms. 2 However, there are subsets of patients who have resistance to oral corticosteroids and need sinus surgery to control the disease, which does not eliminate future recurrences. This scenario has increased the research on new therapies directed to those patients resistant to oral corticosteroids, particularly new biologic agents, such as omalizumab (anti-IgE), mepolizumab (anti-IL-5), or dupilumab (anti-IL-4/IL-13) among others. 3 Therefore the greatest challenge for the future would be to identify biomarkers to appropriately select those corticosteroid-resistant patients who could benefit from new therapies.
Mucins are widely known key components of the airway epithelial mucus layer that contribute to the protection of the sinonasal mucosa from pathogens and irritants through their participation in the mucociliary clearance mechanism. 4 However, recent evidence suggests that mucins are also involved in other less conventional roles, including host defense against airway infection and inflammation, morphogenesis and repair, and treatment response. [5] [6] [7] In contrast to secreted mucins, membrane-tethered mucins are transmembrane proteins anchored to the apical surface of mucosal epithelial cells, with a highly glycosylated N-terminal domain in contact with the outside environment acting as a sensor receptor and a short cytoplasmic tail (CT) that enables its participation in intracellular signaling. 4 Although mucin 1 (MUC1) and mucin 4 (MUC4) membranetethered mucins are overexpressed in nasal polyp (NP) epithelium in comparison with normal nasal mucosa, 8 there is a lack of information about their role. In this regard we recently showed that MUC1 is significantly downregulated in patients with CRSwNP who are resistant to oral corticosteroids. 6 Further analysis revealed that the CT fraction of MUC1 provides anti-inflammatory effects on NP epithelial cells through inhibition of Toll-like receptor (TLR) 2, TLR4, and TLR5. Moreover, MUC1-CT associates with the glucocorticoid receptor (GR) a protein complex, mediating GRa nuclear translocation in response to corticosteroids and allowing its anti-inflammatory effects. 6 In contrast to MUC1, the role of MUC4 on corticosteroid efficacy in patients with CRSwNP is unknown.
The MUC4 gene encodes a membrane-tethered mucin composed of 2 subunits: MUC4a and MUC4b. 9 MUC4a is the extracellular subunit featuring a typical hyperglycosylated region. MUC4b is the transmembrane subunit containing 3 epidermal growth factor (EGF)-like domains (EGF3, EGF1, and EGF2 located from the C-terminus to the N-terminus) and a short CT fragment with potential protein-protein interactions, such as the well-described ErbB2-MUC4b interaction in patients with different types of cancer. 10 Recent evidence showed that MUC4 expression is upregulated in airways under inflammatory conditions 11 and that corticosteroids decrease MUC4 expression in vitro. [11] [12] [13] However, the association of oral corticosteroid efficacy with MUC4 expression, as well as the possible interactions among corticosteroids, GR, and MUC4, are currently unknown.
On the basis of this background, we hypothesized that MUC4 could modulate the systemic corticosteroid response in patients with CRSwNP. Thus we investigated the possible association of NP MUC4 expression with the response to oral corticosteroids in a cohort of patients with CRSwNP. In addition, we evaluated the possible mechanistic link between MUC4b, GRa, and the anti-inflammatory efficacy of corticosteroids. Results observed in this work might help provide new biomarkers to explain corticosteroid response in patients with CRSwNP.
METHODS Patients
This study analyzed data from patients with CRSwNP (n 5 81) enrolled from the Rhinology Unit of Valencia University General Hospital during a 4-year period (2010) (2011) (2012) (2013) (2014) . This work was approved by the local ethics committee, and informed consent was obtained from each subject. Patients with CRSwNP with no clinical and endoscopic response to intranasal corticosteroids for 3 months were cross-sectionally recruited. At the moment of recruitment, all patients had extensive polyps (score 5 2-4 on both sides, see Table E1 in this article's Online Repository at www.jacionline.org). Patient phenotypes were classified as nasal polyps without asthma or aspirin intolerance (NPwA), nasal polyps with aspirin-tolerant asthma (NP-ATA), and nasal polyps with aspirin-intolerant asthma (PN-AIA). Patients started oral corticosteroids (deflazacort) at 1 mg/kg/d for 8 days, followed by 0.5 mg/kg/d for another 7 days, according to routine clinical practice. Corticosteroid resistance was evaluated at day 15 after corticosteroid therapy. Patients unable to reduce more than 1 NP endoscopic score after the oral corticosteroid course were considered resistant to corticosteroids and classified as the nasal polyps resistant to oral corticosteroids (NP-CR) group. The clinical characteristics of all patients before starting oral corticosteroids and at the end of treatment are presented in Table E2 
RESULTS

Expression and distribution of MUC4 is altered in patients with CRSwNP resistant to oral corticosteroids
Eighty-one patients with CRSwNP and no response to intranasal corticosteroids were recruited to initiate a 15-day course of oral corticosteroids. Patients started oral corticosteroids (deflazacort) at 1 mg/kg/d for 8 days, followed by 0.5 mg/kg/d for another 7 days, according to routine clinical practice. Therapy compliance was evaluated by a clinical research pharmacy by means of direct recount of drug containers and personal interview with the patients after therapy ended. At the end of oral therapy, 22 patients were classified as having NP-CR because their NP endoscopic scores were not reduced by more than 1 unit (see the polyp scoring system in Table E1 ). Responder patients were classified as patients with NPwA (n 5 14), NP-ATA (n 5 12), and NP-AIA (n 5 33). Among the 22 patients with NP-CR, 6 of them had NPwA (30% of total NPwA), 2 had NP-ATA (14.3% of total NP-ATA), and 14 had NP-AIA (29.8% of total NP-AIA). The clinical characteristics of all patients before and after oral corticosteroid therapy are defined in Table E2 , and the characteristics of the patients with NP-CR are shown in Table  E3 in this article's Online Repository at www.jacionline.org.
NP biopsy specimens were taken before and after a 2-week course of oral corticosteroids to analyze the possible association of MUC4 expression with corticosteroid response. MUC4 mRNA expression was significantly upregulated before and after oral corticosteroid therapy in the NP tissue of patients with NP-CR (Fig 1, A, and Table E2 ) compared with the other groups, whereas no differences were observed among responders in the NPwA, NP-ATA, and NP-AIA groups (Fig 1, A, and Table E2 ). The same pattern of MUC4 expression was observed between patients with NP-CR showing NPwA, NP-ATA, and NP-AIA (see Table E3 ). In a similar manner MUC4b protein expression was significantly overexpressed in patients with NP-CR, mainly in the NP epithelium, regardless of the stage of oral therapy (Fig 1, B-D) . Furthermore, patients with NP-CR had a decreased MUC1/MUC4 gene expression ratio compared with responder patients, indicating a differential role of MUC1 and MUC4 in corticosteroid responsiveness (Fig 1, E) .
Anti-inflammatory effects of dexamethasone on NP epithelial cells from corticosteroid responders and nonresponders NP epithelial cells were isolated from NP biopsy specimens of responders and nonresponders to oral corticosteroids to explore the anti-inflammatory effects of dexamethasone. Nasal sinus microorganism colonization is present in patients with CRSwNP and contributes to the progression and severity of the disease. Both gram-positive and gram-negative bacteria are common in NP tissue, promoting inflammation through TLR activation. In particular, TLR2 and TLR4 are activated by gram-positive peptidoglycan (PGN) and gram-negative LPS, respectively. In NP epithelial cells isolated from responder patients, both 10 mg/mL PGN or 1 mg/mL LPS significantly induced overexpression of MUC4, which was inhibited by dexamethasone, even to less than control levels in the absence of stimulus, after 24 hours of exposure (Fig 2, A) . Mitogen-activated protein kinase phosphatase 1 (MKP-1) was upregulated by dexamethasone in the presence or absence of the bacterial stimulus (Fig 2, B) . Furthermore, dexamethasone inhibited the release of IL-8 induced by PGN and LPS by 49.9% 6 16.6% and (Fig 2, E) . Furthermore, dexamethasone was unable to induce MKP1 expression and did not inhibit IL-8 and GM-CSF secretion (Fig 2, F-H ). In addition, NP epithelial cells from nonresponder patients released higher IL-8 and GM-CSF amounts than those cells from responder patients in response or absence to PGN or LPS (Fig 2, C , D, G, and H).
Effects of MUC4 on dexamethasone antiinflammatory pathways
Next, experiments were conducted to evaluate the contribution of MUC4 to the anti-inflammatory effects of dexamethasone. Neither MUC4 knockdown nor MUC1 knockdown modified MUC1 or MUC4 expression, respectively, which ruled out that Muc1 and Muc4 regulate each other's expression (see Fig E1 in this article's Online Repository at www.jacionline.org). MUC4 knockdown by RNA interference (siRNA-MUC4) was assayed in BEAS-2B cells after stimulation with LPS or PGN in the presence or absence of dexamethasone. siRNA-MUC4 cells showed significantly lower IL-8 and GM-CSF release after LPS or PGN stimulation than did siRNA(2) stimulated cells (P < .05; see Fig E2, A, and E3 , B, in this article's Online Repository at www.jacionline.org). Dexamethasone inhibited IL-8 secretion by 57.7% 6 6.6% and 37.3% 6 16.1% after LPS and PGN stimulation in siRNA(2) cells, respectively. The percentage inhibition of dexamethasone in siRNA-MUC4 cells was significantly higher, reaching 92.3% 6 14.4% and 99.5% 6 20.9% after LPS and PGN stimulation, respectively (P < .05; see Fig E2, A, and E3, B) . Similar results were found for GM-CSF release. Dexamethasone inhibited GM-CSF secretion by 62.3% 6 9.3% and 65.3% 6 18% in siRNA(2) cells and by 88.2% 6 1% and 80.3% 6 5% in siRNA-MUC4 cells after LPS and PGN stimulation, respectively (P < .05; see Fig E2 , C, and E3, D). Further experiments showed that the increase in MKP1 expression induced by dexamethasone was higher in experiments in each population. Two-way ANOVA was followed by the post hoc Bonferroni test. *P < .05 related to control release in the same subject group. #P < .05 related to the stimulus LPS or PGN.
siRNA-MUC4 cells when compared with siRNA(2) control cells, suggesting that MUC4 gene expression impairs antiinflammatory effects of dexamethasone (see Fig E2, E and F) .
Corticosteroids mediate part of through anti-inflammatory effects through transactivation of genes that encode proteins with anti-inflammatory properties through direct interaction of the agonist-bound GR to glucocorticoid response elements (GREs). In this work cells were transfected with GRE reporter construct in siRNA-MUC4 cells and siRNA(2) cells and incubated with 1 mmol/L dexamethasone for 6 hours. Treatment of 2xGRE BEAS-2B reporter cells with dexamethasone (0.1 nmol/L to 1 mmol/L) for 6 hours induced GRE-dependent transcription in a concentration-dependent manner that was significantly higher in siRNA-MUC4 than in siRNA(2) control cells (see Fig E2, G) .
In siRNA(2) cells both PGN and LPS increase the levels of phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 over that seen in in siRNA-MUC4 cells (see Fig E3, A) . Dexamethasone partially inhibited PGN-and LPS-induced phosphorylation of ERK1/2 in siRNA(2) cells, whereas in siRNA-MUC4 cells the ERK1/2 phosphorylation was completely suppressed (see Fig E3, A) . Contrary effects were observed for MKP1 expression. In siRNA(2) control cells the upregulation of MKP1 protein induced by dexamethasone was higher than that observed in siRNA-MUC4 cells (see Fig E3, B) .
MUC4b interacts differently with the GRa complex in NP epithelial cells from patients with CRSwNP, both responders and nonresponders to oral corticosteroids
NP primary epithelial cells were treated with or without 1 mmol/L dexamethasone for 4 hours to promote GRa nuclear translocation. Nuclear, cytoplasmic, or total protein was extracted and immunoprecipitated with MUC4b or GRa, followed by an immunoblot with the GRa antibody or MUC4b immunoblot. In NP epithelial cells from responders with CRSwNP, coimmunoprecipitation of MUC4b-GRa was absent in the nucleus independent of dexamethasone treatment. In contrast, cytoplasm expressed the MUC4b-GRa complex, expression of which decreased after dexamethasone exposure (Fig 3, A) . Confocal immunofluorescence for GRa and MUC4b revealed that both proteins are coexpressed in the cytoplasm of NP epithelial cells around the nucleus. After addition of dexamethasone, the GRa-MUC4b complex was dissociated, and GRa translated to the nucleus, whereas MUC4b remained in the cytoplasm (Fig  3, A) . Different results were observed in NP epithelial cells from corticosteroid-resistant patients. NP epithelial cells showed a broad MUC4b distribution in cytoplasm and nucleus. MUC4b-GRa complex was present in nucleus and cytoplasm. Confocal images corroborated immunoprecipitation experiments, suggesting that in NP epithelial cells from corticosteroid-resistant patients, dexamethasone is unable to induce GRa-MUC4b complex dissociation.
Effect of MUC4 overexpression on antiinflammatory effects of dexamethasone in the HEK293/Tet3G/TRE3G-MUC4 stable cell line
The HEK293/Tet3G/TRE3G-MUC4 stable cell line was created with the doxycycline-inducible MUC4 expression system and the full-length MUC4-inducible plasmid CS-H2247-pTREG (see Fig E4 in this article's Online Repository at www.jacionline. org). Doxycycline at 1 nmol/L, 10 nmol/L, 100 nmol/L, and 1 mmol/L induced 2-, 19-, 42-, and 100-fold MUC4 increased expression, respectively, after 24 hours of incubation (see Fig  E5, A, in this article's Online Repository at www.jacionline. org). The HEK293/Tet3G/TRE3G-MUC4 stable cell line was incubated with or without doxycycline (100 nmol/L and 1 mmol/L) for 24 hours, followed by the addition of dexamethasone (0.1 nmol/L-1 mmol/L) for 2 hours before LPS stimulation for 24 hours.
The IL-8 percentage inhibition of dexamethasone in control cells was 100%, which is significantly higher than in cells pretreated with 100 nmol/L and 1 mmol/L doxycycline, reaching 73.6% 6 4% and 48.7% 6 0.8% inhibition, respectively (see Fig  E5, B) . In other experiments HEK293/Tet3G/TRE3G-MUC4 cells were transfected with GRE reporter construct and incubated with doxycycline (100 nmol/L or 1 mmol/L) for 24 hours, followed by the addition of dexamethasone (0.1 nmol/L to 1 mmol/L) for 6 hours. Treatment of 2xGRE HEK293/Tet3G/ TRE3G-MUC4 cells with dexamethasone (0.1 nmol/L to 1 mmol/L) for 6 hours induced GRE-dependent transcription in a concentration-dependent manner that was significantly higher in the absence of doxycycline (see Fig E5, C) . 
DISCUSSION
Findings showed in this work provide first evidence on the participation of MUC4 in the corticosteroid resistance seen in patients with CRSwNP. MUC4 was significantly overexpressed in NP epithelial cells of corticosteroid-resistant patients when compared with those of CRSwNP responder patients. Mechanistic experiments revealed that TLR2 and TLR4 bacterial agonists induce MUC4 overexpression that is reversed by dexamethasone in responder patients but not in corticosteroidresistant patients. MUC4 knockdown attenuated the inflammatory response elicited by TLR2 and TLR4 agonists and improved the anti-inflammatory effects of dexamethasone. In NP epithelial cells from responder patients, MUC4b formed a complex with GRa in the cytoplasm that was dissociated in response to dexamethasone to promote translocation of GRa to the nucleus. However, in NP epithelial cells from corticosteroid-resistant patients, MUC4b was overexpressed, and MUC4b-GRa complex was present in cytoplasm and nucleus remaining as a complex, regardless of the addition of dexamethasone, thus impairing the correct binding of GRa to GRE in promoter regions of glucocorticoid-inducible genes, such as MKP1, which might explain, in part, the effect of MUC4 on corticosteroid resistance of patients with CRSwNP.
This work is an extension study of previously reported clinical translational research 6 in which the membrane-tethered MUC1-CT was identified as a molecular tool that forms a complex with GRa, enabling GRa nuclear translocation in response to dexamethasone and the subsequent corticosteroid anti-inflammatory effects. 6 In this regard patients with NP-CR had lower MUC1-CT-GRa complexes in NP tissue along with lower expression of MKP1 and GRa than that observed in responder patients. Furthermore, dexamethasone increased MUC1-CT expression as part of its anti-inflammatory effects because MUC1-CT also inhibited activation of TLR proinflammatory signals.
14 The hypothesis derived from this previous study was that the membrane-tethered MUC4 mucin could play some role in corticosteroid efficacy in patients with CRSwNP.
In contrast to MUC1, the role of MUC4 has been described only in the context of different types of cancers. 15 Experimental evidence indicates that MUC4b binds the receptor ErbB2 in plasma membrane and modulates its localization, 16 phosphorylation, and downstream signaling, 17 thus promoting growth, motility, or differentiation of cancer cells. 18 However, MUC4b can play different roles independently of ErbB2, promoting, for example, the activation of c-Jun N-terminal kinase pathway and cell cancer migration independently of the ErbB2 receptor interaction. 19 As occurs with MUC1 mucin, MUC4 is expressed in nasal and bronchial epithelial cells of healthy subjects. 20 Previous reports have shown that MUC4 is overexpressed in NPs when compared with nasal mucosa, 8, 11 and its expression is upregulated under inflammatory conditions 13, 21 and after fungal, bacterial, or rhinovirus injury. 11, 21, 22 FIG 3 . MUC4b is coexpressed with GRa in NP epithelial cells. The nuclear, cytoplasmic, or total protein immunoprecipitates (IP) of MUC4b or GRa were collected from NP primary epithelial cells from responder (n 5 6; A) and nonresponder (n 5 8; B) patients and incubated in the presence or absence (basal) of dexamethasone (Dex; 1 mmol/L) for 4 hours. Immunoprecipitates were immunoblotted (IB) with the opposite antibody GRa or with the same antibodies used for immunoprecipitation as controls. The IgG isotype was used as a negative control for immunoprecipitation. NP epithelial cells were fixed, permeabilized, and used for MUC4b (red) and GRa (green) immunostaining. Under basal conditions, MUC4b colocalized with GRa in the cytoplasm of responder patients and throughout the cell in nonresponder patients. After dexamethasone stimulation, GRa dissociated from MUC4b and translocated to the nucleus in cells from responder patients but remained colocalized with MUC4b in cytoplasm and nucleus in nonresponder patients. Colocalization was analyzed with a confocal spectral microscope (Leica TCS SP2; Leica, Wetzlar, Germany) that generated a bidimensional cytofluorogram that selected common localized points of both antibodies (white color). 49-6-Diamidino-2-phenylindole dihydrochloride (DAPI), blue nuclei. Scale bars 5 10 mm.
Recent data also indicate that MUC4 is overexpressed in bronchial epithelium of patients with severe uncontrolled asthma when compared with that of healthy subjects or patients with mild-to-moderate asthma. 23 In this work we analyzed the role of MUC4 on corticosteroid efficacy. The overexpression of MUC4b was significantly associated with the lack of response to oral corticosteroids in patients with CRSwNP. Opposite results were observed for MUC1 expression. In fact, the lower ratio between MUC1/MUC4 expression in NPs clearly differentiated responder and nonresponder patients. Although the effect of MUC4 on corticosteroid efficacy is not known, previous observations could indicate some contribution. Thus, for example, airway bacterial (mainly Staphylococcus aureus) and rhinovirus airway colonization increase corticosteroid insensitivity 24, 25 and MUC4 expression. 11, 22 In addition, MUC4 is overexpressed in patients with severe uncontrolled asthma 23 that is particularly resistant to corticosteroids. 26 In this work the incidence of corticosteroid resistance was similar among patients with NPs without asthma and patients with asthma, perhaps because asthmatic patients participating in this study had mild-tomoderate well-controlled asthma. 23 However, the association of MUC4 overexpression with corticosteroid resistance could be only an observation secondary to NP inflammation without any direct relation to corticosteroid mechanistic pathways. In this regard several mechanisms have been proposed to contribute to the loss of corticosteroid efficacy in patients with CRSwNP, such as the loss of MUC1, GRa, and MKP1 expression in NP tissue 6 or the increase of nuclear factor kB, GRb, phosho-ERK1/2, c-Jun N-terminal kinase, and GRSer226 hyperphosphorylation. 6, [27] [28] [29] This fact indicates that corticosteroid resistance is an acquired and progressive condition that can depend on several multiple molecular pathways. In this work we focused on the effect of MUC4 on dexamethasone's anti-inflammatory effects. In NP epithelial cells from responder patients, we observed that TLR2 and TLR4 agonists increased the expression of MUC4 and the release of IL-8 and GM-CSF, which were significantly inhibited by dexamethasone. Similar results have been observed previously in human NP epithelial cells, showing an inhibitory effect of dexamethasone on IL-1b or LPS-induced MUC4 overexpression. 11, 13 Unlike in responder patients dexamethasone did not reduce the expression of MUC4 and release of IL-8 and GM-CSF in NP epithelial cells from corticosteroid-resistant patients. To identify the contribution of MUC4 to the anti-inflammatory effects of corticosteroids, we conducted mechanistic experiments by using MUC4 knockdown by RNA interference. Thus in siRNA-MUC4 cells TLR2 and TLR4 agonists significantly increased the release of IL-8 and GM-CSF when compared with siRNA(2) control cells, suggesting a role for MUC4 in the inflammatory process. Furthermore, dexamethasone showed an improved antiinflammatory effect in siRNA-MUC4 cells. These results were mechanistically corroborated in siRNA-MUC4 cells, in which the activation of TLR2/TLR4 induced lower ERK1/2 phosphorylation that was nearly suppressed by dexamethasone. These results suggested that MUC4b could play some role collaborating in TLR activation or inhibiting corticosteroid efficacy. The last hypothesis was tested measuring levels of the glucocorticoid-enhanced MKP1 protein, which is induced as a consequence of the interaction of GRa with GRE in promoter regions of corticosteroid-inducible genes to inhibit ERK1/2 phosphorylation and the consequent inflammation. 30 In this regard dexamethasone significantly increased MKP1 expression in NP epithelial cells from responder patients and in siRNA-MUC4 cells when compared with cells from nonresponders or siRNA(2) cells, respectively. Furthermore, dexamethasone significantly increased GRE reporter signal in siRNA-MUC4 cells when compared with that in siRNA(2) cells, confirming the hypothesis by which MUC4 can inhibit transactivation of GRa. Next, we analyzed the possible interaction of MUC4b with the GRa complex, as well as its possible effect on nuclear translocation. As occurs with MUC1-CT, the mucin MUC4b also contains a cytoplasm tail that can interact with other intracellular proteins to modulate different signal pathways. 15 However, in contrast to MUC1-CT, there is no current evidence of MUC4b intracellular interactions. In this work we immunoprecipitated MUC4b in NP epithelial cells from responders and from corticosteroid-resistant patients after 4 hours of dexamethasone exposure. In NP epithelial cells from responder patients, the MUC4b-GRa complex was absent in the nucleus and restricted to cytoplasm, mainly around the nucleus. After dexamethasone exposure, the MUC4b-GRa complex was dissociated, and GRa was released to the nucleus. However, in cells from nonresponder patients, the MUC4b-GRa complex was present in the cytoplasm and nucleus and was not dissociated by dexamethasone. These results indicate that MUC4b could work by blocking the correct interaction of GRa with GRE DNA regions. GRa forms different dynamic complexes with multiple proteins that modulate its correct function. In the absence of corticosteroids, GRa resides in the cytoplasm in a multimeric chaperone complex consisting of heat shock protein (hsp) 90, hsp70, hsp90-binding protein p23, immunophilins, MUC1-CT, and other factors to prevent its degradation and assist in its maturation. 6, 31 The GRa complex translocates to the nucleus in response to corticosteroids and with the participation of nuclear pore complex, including importins and nucleoporins. GRa also builds a complex with the chaperone calreticulin, forming an inactive complex in the nucleus to export GRa to the cytoplasm. 32, 33 Interestingly, MUC4b can also form a complex with calreticulin, which might explain, in part, the inactivation of GRa by a multimeric MUC4b-calreticulin-GRa complex. 34 However, the last proposed mechanism is only a speculation and reveals the necessity of further investigations to appropriately dissect the exact mechanism mediating the MUC4b-GRa relation.
To better understand the direct effect of MUC4 overexpression on corticosteroid resistance, we created a HEK293/Tet3G/ TRE3G-MUC4 stable cell line based in tetracycline transactivator-inducible gene expression system. Cells incubated with doxycycline increased the expression of MUC4 to up of 100-fold. In doxycycline-treated HEK293/Tet3G/TRE3G-MUC4 cells dexamethasone showed less inhibitory effect on LPS-induced IL-8 release and less GRE induction and MKP1 expression. Furthermore, the MUC4-GRa complex was not dissociated in doxycycline-treated HEK293/Tet3G/TRE3G-MUC4 cells overexpressing MUC4, which mimicked the observations in NP epithelial cells from nonresponder patients and corroborated the effect of MUC4 overexpression on corticosteroid insensitivity. However, there is a lack of evidence whether MUC4 might play a role in the corticosteroid resistance seen in other tissues or inflammatory cells, as well as in patient with other airway diseases in which it is possible to observe a loss of corticosteroid efficacy, such as severe asthma or chronic obstructive pulmonary disease. 26 It should be emphasized that J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 mechanistic experiments were done in the BEAS-2B bronchial epithelial cell line and the MUC4-overexpressing HEK293 cell line. Both are biologically different from NP primary epithelial cells, and this represents a potential limitation of our study. In summary, we demonstrated a new role for MUC4 in modulating the loss of the anti-inflammatory effects of corticosteroids in patients with CRSwNP, which might help explain the interindividual differences in response to corticosteroids.
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Key messages d MUC4 overexpression on NP epithelium of patients with
CRSwNP is a biomarker of oral corticosteroid resistance.
d MUC4 overexpression impairs the correct antiinflammatory effects of corticosteroids by forming a MUC4-GRa inhibitory complex.
METHODS Patients
This study analyzed data from patients with CRSwNP (n 5 81) enrolled from the Rhinology Unit of Valencia University General Hospital during a 4-year period (2010-2014). This work was approved by the local ethics committee, and informed consent was obtained from each subject. This study incorporated 22 patients from a previously published work on MUC1's role in corticosteroid efficacy, which shares the same clinical design as the present study. E1 Patients with CRSwNP with no clinical and endoscopic response to intranasal corticosteroids for 3 months were cross-sectionally recruited. In this study NPs were defined based on endoscopic findings of bilateral polyps originating from the middle meatus and/or confirmation of NPs by using computed tomography, according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012 guidelines. E2 All patients had extensive polyps (score, 2-4 on both sides; Table E1 ). Atopic status was evaluated by using a skin prick test or assays for specific IgEs against common inhaled allergens. The diagnosis of aspirin intolerance was confirmed by means of lysineaspirin nasal challenge, as previously described. E3 The diagnosis of asthma was determined by a pneumologist. All subjects were free of upper respiratory tract clinical infections for the 4 weeks preceding the oral corticosteroid therapy. None of the subjects used other medications (eg, antibiotics or antileukotrienes) for 4 weeks before starting oral corticosteroids.
At the moment of recruitment, patient phenotypes were classified as NPwA, NP-ATA, and NP-AIA. Patients started oral corticosteroids (deflazacort) at 1 mg/kg/d for 8 days, followed by 0.5 mg/kg/d for another 7 days, according to routine clinical practice. Therapy compliance was evaluated by a clinical research pharmacy using direct recount of drug containers and personal interviews with the patients after therapy ended. Corticosteroid resistance was evaluated at day 15 after corticosteroid therapy. Patients who were unable to reduce more than 1 NP endoscopic score after oral corticosteroid course were considered resistant to corticosteroids and classified as the NP-CR group. The clinical characteristics of all patients before starting oral corticosteroids and at the end of treatment are presented in Table E2 . Patients of the NP-CR group had the NPwA (n 5 6), NP-ATA (n 5 2), and NP-AIA (n 5 14) phenotypes, and their characteristics are defined in Table E3 .
NP tissues were sampled before and after oral corticosteroid therapy to isolate nasal epithelial cells and to analyze tissue mRNA and protein expression, as well as protein epithelial location, by means of immunohistochemistry.
NP epithelial cell isolation and cell culture
NP samples (approximately 5 3 5 mm) were washed with sterile physiologic serum and plated on collagen-coated culture dishes (10 mg/cm 2 rat type I collagen; Sigma, St Louis, Mo) in bronchial epithelial growth medium (comprising bronchial epithelial basal medium supplemented with bovine pituitary extract at 52 mg/mL, hydrocortisone at 0.5 mg/mL, human recombinant EGF at 25 ng/mL, epinephrine at 0.5 mg/mL, transferrin at 10 mg/mL, insulin at 5 mg/mL, retinoic acid at 50 nmol/L, triiodo-Lthyronine at 6.5 ng/mL, gentamicin at 40 mg/mL, amphotericin B at 50 ng/mL, BSA at 1.5 mg/mL, and retinoic acid at 0.05 mmol/L).
NPs were oriented with the epithelial layer to be in contact with the culture plate. Cultures were kept in a 5% CO 2 humidified incubator at 378C. After a period of approximately 1 to 2 weeks, NP epithelial cells were observed around the polyps and used for in vitro mechanistic experiments. The identity of the monolayer as NP epithelial cells was affirmed by using morphologic criteria and immunofluorescence for cytokeratin 18 (KRT18), as well as subsequent in vitro differentiation in an air-liquid interface as pseudostratified NP epithelium with basal cells, ciliated cells, columnar cells, and goblet cells, as previously outlined. E4 Cell viability was assessed by means of vital trypan blue exclusion analysis with the Countness automated cell counter (Life Technologies, Madrid, Spain). Cell viability was greater than 98% in all cell cultures tested in this work. Experiments with primary nasal epithelial cells were performed at passage 1.
The bronchial epithelial BEAS-2B cell line was obtained from the American Type Culture Collection and cultured with the same culture medium and conditions as the primary NP epithelial cells described above at 378C in a 5% CO 2 atmosphere in humidified air. The culture medium was replaced every 48 hours.
Immunohistochemistry and immunofluorescence analysis
For immunohistochemical analysis of human NPs, the tissue was fixed, embedded in paraffin, cut into sections (4-6 mm), and stained with hematoxylin, as reported previously. E5 The sections were incubated with rabbit anti-human polyclonal MUC4b antibody (NBP1-52193; Novus Biologicals, Littleton, Colo) for 24 hours at 48C. A secondary anti-rabbit antibody (1:100; Vector Laboratories, Burlingame, Calif) with avidin-biotin complex/horseradish peroxidase was used for immunohistochemistry. The nonimmune IgG isotype was used as a negative control and yielded no signal in all cases (data not shown). Stained slices were scored by a blinded pathologist under a Nikon Eclipse TE200 light microscope (Nikon, Tokyo, Japan), and representative photographs were taken (10 slices per patient). Staining intensity was analyzed in NP epithelium. Staining intensity for MUC4b antibody was scored on a scale of 0 to 3 (0, negative; 1, weak; 2, moderate; and 3, strong immunoreactivity). The percentage of cells positive for MUC4b within NP epithelium was scored on a scale of 1 to 4 as follows: 1, 0% to 25% positive; 2, 26% to 50% positive; 3, 51% to 75% positive; and 4, 76% to 100% positive. The score of the staining intensity and percentage of immunoreactive cells were then multiplied to obtain a composite score ranging from 0 to 12.
The in vitro cell culture of NP epithelial cells was fixed (4% paraformaldehyde for 30 minutes at room temperature) after appropriate treatments. Cells were permeabilized (20 mmol/L HEPES at pH 7.6, 300 mmol/L sucrose, 50 mmol/L NaCl, 3 mmol/L MgCl 2 , and 0.5% Triton X-100), blocked (10% goat serum in PBS), and incubated with the primary antibodies rabbit anti-human polyclonal MUC4-b antibody (NBP1-52193, Novus Biologicals) and mouse anti-human monoclonal GRa antibody (catalog no. 611227; BD Biosciences, San Jose, Calif) overnight at 48C, followed by secondary antibody anti-rabbit/mouse rhodamine/fluorescein isothiocyanate (1:100; Molecular Probes, Eugene, Ore).
In Fig 3, colocalization of MUC4-b and GRa was performed with a confocal spectral Leica TCS SP2 microscope at 31000 magnification and 33 zoom. Red (HeNe 543 nm), green (HeNe 488 nm), and blue (Ar 351 nm and 364 nm) lasers were used. Colocalization studies were performed with Leica confocal software v2.61. A bidimensional cytofluorogram was created between different green and red intensity points of the cell image. The cell images with colocalized points of the 2 laser canals were changed to a white color in the cell image.
Real-time RT-PCR and siRNA experiments
Total RNA was isolated from NP tissue by using TriPure Isolation Reagent (Roche, Indianapolis, Ind). The integrity of the extracted RNA was confirmed with the Bioanalyzer (Agilent, Palo Alto, Calif). Reverse transcription was performed in 300 ng of total RNA with a TaqMan reverse transcription reagent kit (Applied Biosystems, Perkin-Elmer, Foster City, Calif). cDNA was amplified with specific primers and probes predesigned by Applied Biosystems for MUC1 (Hs00159357_m1), MUC4 (Hs00366414_m1), and MKP1 (Hs00610256_g1) in a 7900HT Fast Real-Time PCR System (Applied Biosystems) by using Universal Master Mix (Applied Biosystems).
Expression of the target gene was expressed as the fold increase or decrease relative to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control (4310884E, Applied Biosystems). The mean value of the replicates for each sample was calculated and expressed as the cycle threshold (Ct). The level of gene expression was then calculated as the difference (DCt) between the Ct value of the target gene and the Ct value of GAPDH. The fold changes in the target gene mRNA levels were designated 2 2DCt . J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 siRNA, including the scrambled siRNA control, was purchased from Ambion (Cambridge, United Kingdom). MUC4 gene-targeted siRNA (identification no. s9073) was designed by Ambion. BEAS-2B cells were transfected with siRNA (50 nmol/L) in serum and antibiotic-free medium. After 6 hours, the medium was aspirated and replaced with medium containing serum for a further 42 hours before cell stimulation. The transfection reagent used was lipofectamine-2000 (Invitrogen, Paisley, United Kingdom) at a final concentration of 2 mg/mL. MUC4 knockdown was evaluated in BEAS-2B cells by means of Western blotting and RT-PCR by using MUC4b antibody and MUC4 primers and probe, as described above. MUC4 expression in MUC4 knockdown experiments was always less than 10% of MUC4 expression in siRNA(2) control cells (data not shown).
Western blot analysis
Western blot analysis was used to detect changes in NP tissue and BEAS-2B protein expression of MUC4b, mouse anti-human monoclonal phospho-ERK1/2 (catalog no. M9692, Sigma-Aldrich), rabbit anti-human polyclonal MKP1 (B1099; Assay Biotech, Sunnyvale, Calif), and GRa antibody (GRa; catalog no. 611227, BD Biosciences). NP tissue or BEAS-2B cells were homogenized or scraped from a confluent 25-cm 2 flask and lysed on ice with a lysis buffer comprising complete inhibitor cocktail plus 1 mmol/L EDTA (Roche Diagnostics, West Sussex, United Kingdom) with 20 mmol/L TRIS base, 0.9% NaCl, 0.1% Triton X-100, 1 mmol/L dithiothreitol, and 1 mg/mL pepstatin A. Nuclear and cytoplasm protein extraction was performed with a nuclear active motif extraction kit (Active Motif Europe, Rixensart, Belgium), according to the manufacturer's protocol. The Bio-Rad assay (Bio-Rad Laboratories, Herts, United Kingdom) was used according to the manufacturer's instructions to quantify the level of protein in each sample to ensure equal protein loading. SDS-PAGE was used to separate the proteins according to their molecular weight. Briefly, 15 mg of proteins (denatured) along with a molecular weight protein marker (Bio-Rad Kaleidoscope marker, Bio-Rad Laboratories) was loaded onto an acrylamide gel consisting of a 5% acrylamide stacking gel stacked on top of a 10% acrylamide resolving gel and run through the gel by means of application of 100 V for 1 hour. Proteins were transferred from the gel to a polyvinylidene difluoride membrane by using a wet-blotting method. The membrane was blocked with 5% Marvel in PBS containing 0.1% Tween 20, probed with the antibodies described above, and normalized to total mouse anti-human b-actin (1:1000) antibody (mAb, catalog no. A1978; Sigma) or total rabbit anti-human ERK1/2 (1:1000) antibody (mAb; catalog no. 4695; Cell Signaling, Boston, Mass) as appropriate. The enhanced chemiluminescence method of protein detection with enhanced chemiluminescence reagents (ECL Plus; Amersham GE Healthcare, Buckinghamshire, United Kingdom) was used to detect labeled proteins. Densitometry of films was performed with Image J 1.42q software (available at http://rsb.info.nih.gov/ij/; National Institutes of Health, Bethesda, Md). Results of target protein expression are expressed as the percentage of the densitometry of the endogenous controls b-actin or total ERK1/2, as appropriate.
Immunoprecipitation
Equal amounts of protein (200 mg) from total, cytoplasmic, or nuclear extracts were incubated with 2 mg of anti-GRa or anti-MUC4b antibodies and the IgG isotype control. Immune complexes were precipitated with protein G on Sepharose 4B fast flow beads (P-3296; Sigma) overnight at 48C. After washing 3 times with NET buffer containing 50 mmol/L Tris-HCl at pH 8.0, 150 mmol/L NaCl, and 0.1% Nonidet P-40, the bound materials were eluted from the immunoprecipitates in reducing SDS-PAGE loading buffer containing 10% SDS, 1 mol/L Tris-HCl at pH 6.8, 50% glycerol, 10% 2-mercaptoethanol, and 2% bromophenol blue at 1008C for 10 minutes. Immunoprecipitated protein complexes were assayed by means of Western blotting, as described above, and probed with anti-GRa or anti-MUC4b antibodies, as appropriate.
GRE transfection assay
BEAS-2B epithelial cells were seeded (40,000 cells/well) and cultured for 24 hours in a 5% CO 2 /air atmosphere at 378C in 96-well plates containing Dulbecco modified Eagle medium (DMEM). The Cignal GRE Reporter Assay Kit (catalog no. 336841; Qiagen, Hilden, Germany) was used to monitor the activity of GR-induced signal transductions pathways in cultured cells, according to the manufacturer's indications. First, cells were transfected with MUC4 gene-targeted siRNA or scrambled siRNA control, as described above. Twenty-four hours later, cells were transfected with Cignal Reporter (100 ng), Cignal negative control (100 ng) and Cignal positive control (100 ng) in Opti-MEM serum-free culture medium using Lipofectamine 2000 Reagent (Invitrogen) as a transfection reagent. Subsequently, cells were incubated with the transfection reagents at 378C in a 5% CO 2 
After this 6-hour period, the luciferase assay was developed by using the Dual-Luciferase Reporter Assay System (catalog no. 1910; Promega, Madison, Wis), according to the manufacturer's protocol for developing the assay. In brief, growth medium was removed from the cultured cells, and surfaces of the cultured cells were washed gently with PBS. After removing completely the rinse solution, Passive Lysis Buffer 13 was added. The culture plate was then placed on an orbital shaker, with gentle shaking at room temperature for 15 minutes. In the meantime, Luciferase Assay Reagent II (LAR II) was prepared by resuspending the provided lyophilized Luciferase Assay Substrate in 10 mL of the supplied Luciferase Assay Buffer II. A volume of 100 mL of LAR II was predispensed in the appropriate number of wells of a white 96-well plate. Then a volume of 20 mL of cell lysate was added to the wells containing LAR II and mixed by means of pipetting 2 or 3 times. The white plate was placed in the luminometer (Victor, PerkinElmer Inc, Zaventem, Belgium), reading was initiated, and firefly luciferase activity was measured. In the meantime, the Stop & Glo Reagent (Promega) was prepared, just before use, by diluting 1 volume of the Stop & Glo Substrate to 50 volumes of Stop & Glo Buffer. After the first measure, 100 mL of Stop & Glo Reagent was dispensed in the corresponding wells. The plate was replaced in the luminometer, a second reading was initiated, and the Renilla Luciferase activity was recorded. Data are expressed as 23 GRE fold induction of luciferase relative to unstimulated cells.
In vitro stimulations
For the in vitro studies, primary NP epithelial cells or BEAS-2B cells were stimulated with the TLR2 agonist PGN (10 mg/mL; InvivoGen, San Diego, Calif) or the TLR4 agonist LPS (Ultrapure LPS, E coli 0111:B4; 1 mg/mL; InvivoGen) for the indicated times. Dexamethasone (1 mmol/L, Sigma) was added 2 hours before stimulus. In other experiments cells underwent knockout for the MUC4 gene for 48 hours and stimulation, as described above, in the presence or absence of dexamethasone.
ELISA for IL-8 and GM-CSF
IL-8 and GM-CSF levels were determined in cell supernatants by using a commercially available ELISA kit for IL-8 and GM-CSF (catalog nos. DY208 and DGM00; R&D Systems, Nottingham, United Kingdom), according to the manufacturer's protocol.
Doxycycline-induced MUC4 expression of the HEK293/Tet3G/TRE3G-MUC4 stable cell line
The HEK293 cell line was acquired from the American Type Culture Collection and cultured in DMEM (Lonza, Madrid, Spain), with 10% FBS, 0.4 mg/mL G418 (Geneticin; Thermo Fisher Scientific, Madrid, Spain), and 0.8 mg/mL puromycin (Thermo Fisher Scientific) at 378C in a 5% CO 2 atmosphere in humidified air.
Transfection of HEK293 cells with pEf-1a-Tet3G plasmid was performed, according to the manufacturer's protocol (Tet-On 3G Inducible Expression System; catalog no. PT5148-1 [010814]; Clontech Laboratories, Mountain View, Calif).
HEK293 cells were seeded into 6-well plates with 2 mL of medium per well to make the cells 90% confluent. Two mix reactions were created: for mix A, 2.4 mg of pEF-1a-Tet3G plasmid was diluted in 125 mL of Opti-MEM medium, and for mix B, 5 mL of Lipofectamine 2000 (Thermo Fisher Scientific) was diluted with 125 mL of Opti-MEM medium and incubated at room temperature for 5 minutes. Mixes A and B were mixed and incubated at room temperature for 20 minutes. Mix solution was added to HEK293 cells with 2 mL of culture medium (DMEM 1 10% FBS) and incubated in CO 2 incubator at 378C for 40 hours. After the culture time period, cells were trypsinized, serial diluted in 10-cm dishes with culture medium (DMEM, 10% FBS, and 0.4 mg/mL G418), and cultured for 2 weeks until the colonies were visible. When clones were visible, a total of 80 clones were selected by using a clone cylinder. Clones were cultured in 96-well plates and split into 3 sets for each clone. One set of clones was kept in culture. The other 2 sets were transfected with pTRE3G-Luc reporter plasmid. Twenty-four hours after transfection, we induced the cells with 1 mg/mL doxycycline (for each clone, one for uninduced and one for doxycycline induced) for another 24 hours. We then tested luciferase activity using the GeneCopoeia firefly luciferase kit (Luc-Pair Firefly Luciferase HS Assay Kit; catalog no. LF007; GeneCopeia, Rockville, Md). The clone showing the best doxycycline-induced luciferase activity was selected as the best clone for the HEK293/Tet3G stable cell line. We then went back to the set culture without transfection of pTRE3G-Luc and cultured it as the HEK293/Tet3G Cell Bank. From the HEK293/Tet3G cell line, we used the same transfection method to cotransfect CS-H2247-pTRE3G (2.4 mg, Fig E5) and the puromycin linear marker (0.12 mg) into 6-well plate. Forty hours after selection, we serial diluted the transfected cells with 0.4 mg/mL G418 and 0.8 mg/mL puromycin in 10-cm dishes. Using the same protocol, we then picked 20 single clones for clone screening.
Each stable clone was duplicated, one set kept in culture as a cell bank and the other set used to test MUC4 expression by using RT-PCR. For each clone to be tested, cells were split into 2 wells equally. One well was induced by 1 mmol/L doxycycline for 24 hours. The other was not induced with doxycycline. Gene sequence and CS-H2247-pTRE3G MUC4 full-length plasmid is shown in Fig E4 and online repository data 2 (full sequence). Doxycycline did not induce changes in cell viability at the concentrations used in this work, as assessed by using the trypan blue assay (data not shown).
Statistical analysis
Statistical analysis was carried out by using parametric or nonparametric analysis, as appropriate. A P level of less than .05 was considered to indicate statistical significance. In the NP tissue experiments, when the comparisons involved only 2 groups, between-group differences were analyzed by using the Mann-Whitney test. When comparisons involved several groups (NPwA, NP-ATA, NP-AIA, and NP-CR), a nonparametric 1-way ANOVA (Kruskal-Wallis test) was first performed in the case of a global significant difference; between-group comparisons were assessed by using the Dunn post hoc test, which generalizes the Bonferroni adjustment procedure.
In vitro mechanistic cell experiments were performed in primary NP epithelial cells or BEAS-2B cells. In these cases results were expressed as means (SEMs) of n experiments because a normal distribution for each data set was confirmed by means of histogram analyses and the KolmogorovSmirnov test. Statistical analysis was carried out by using parametric analysis. Two-group comparisons were analyzed with the 2-tailed Student paired t test for dependent samples and the unpaired t test for independent samples. Multiple comparisons were performed by using 1-or 2-way ANOVA, followed by the Bonferroni post hoc test. The percentage of inhibition of IL-8 and GM-CSF secretion was calculated, considering the increment between control (basal release) and stimulus (PGN or LPS) to be 100% of response, and the percentage inhibition of dexamethasone was calculated respect the 100% of response.
The CS-H2247-pTRE3G (with G63074) plasmid sequence is as follows :  CTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGAAGAGTTT  ACTCCCTATCAGTGA  TAGAGAACGTATGCAGACTTTACTCCCTATCAGTGATAGAGAACG  TATAAGGAGTTTACT  CCCTATCAGTGATAGAGAACGTATGACCAGTTTACTCCCTATCAG  TGATAGAGAACGTAT  CTACAGTTTACTCCCTATCAGTGATAGAGAACGTATATCCAGTTT  ACTCCCTATCAGTGA  TAGAGAACGTATAAGCTTTAGGCGTGTACGGTGGGCGCCTATAA  AAGCAGAGCTCGTTTA  GTGAACCGTCAGATCGCCTGGAGCAATTCCACAACACTTTTGTC  TTATACCAACTTTCCG  TACCACTTCCTACCCTCGTAAAGTCGACACCGGGGCCCAGATCT  gccaccATGAAGGGGG  CACGCTGGAGGAGGGTCCCCTGGGTGTCCCTGAGCTGCCTGTG  TCTCTGCCTCCTTCCGC  ATGTGGTCCCAGGAGTTTCCCTCTTCCCCTATGGGGCAGGCGCC  GGGGACCTGGAGTTCG  TCAGGAGGACCGTGGACTTCACCTCCCCACTCTTCAAGCCGGC  GACTGGCTTCCCCCTTG  GCTCCTCTCTCCGTGATTCCCTCTACTTCACAGACAATGGCCAG  ATCATCTTCCCAGAGT  CAGACTACCAGATTTTCTCCTACCCCAACCCACTCCCAACAGG  CTTCACAGGCCGGGACC  CTGTGGCCCTGGTGGCTCCGTTCTGGGACGATGCTGACTTCTCC  ACTGGTCGGGGGACCA  CATTTTATCAGGAATACGAGACGTTCTATGGTGAACACAGCCTGC  TAGTCCAGCAGGCCG  AGTCTTGGATTAGAAAGATGACAAACAACGGGGGCTACAAGG  CCAGGTGGGCCCTAAAGG  TCACGTGGGTCAATGCCCACGCCTATCCTGCCCAGTGGACCCTC  GGGAGCAACACCTACC  AAGCCATCCTCTCCACGGACGGGAGCAGGTCCTATGCCCTGTTT  CTCTACCAGAGCGGTG  GGATGCAGTGGGACGTGGCCCAGCGCTCAGGCAACCCGGTGC  TCATGGGCTTCTCTAGTG  GAGATGGCTATTTCGAAAACAGCCCACTGATGTCCCAGCCAGTG  TGGGAGAGGTATCGCC  CTGATAGATTCCTGAATTCCAACTCAGGCCTCCAAGGGCTGCAG  TTCTACAGGCTACACC  GGGAAGAAAGGCCCAACTACCGTCTCGAGTGCCTGCAGTGGCT  GAAGAGCCAGCCTCGGT  GGCCCAGCTGGGGCTGGAACCAGGTCTCCTGCCCTTGTTCCTG  GCAGCAGGGACGACGGG  ACTTACGATTCCAACCCGTCAGCATAGGTCGCTGGGGCCTCGGC  AGTAGGCAGCTGTGCA  GCTTCACCTCTTGGCGAGGAGGCGTGTGCTGCAGCTACGGGCC  CTGGGGAGAGTTTCGTG  AAGGCTGGCACGTGCAGCGTCCTTGGCAGTTGGCCCAGGAACT  GGAGCCACAGAGCTGGT  GCTGCCGCTGGAATGACAAGCCCTACCTCTGTGCCCTGTACCAG  CAGAGGCGGCCCCACG  TGGGCTGTGCTACATACAGGCCCCCACAGCCCGCCTGGATGTT  CGGGGACCCCCACATCA  CCACCTTGGATGGTGTCAGTTACACCTTCAATGGGCTGGGGGAC  TTCCTGCTGGTCGGGG  CCCAAGACGGGAACTCCTCCTTCCTGCTTCAGGGCCGCACCGCC  CAGACTGGCTCAGCCC  AGGCCACCAACTTCATCGCCTTTGCGGCTCAGTACCGCTCCAGC  AGCCTGGGCCCCGTCA  CGGTCCAATGGCTCCTTGAGCCTCACGACGCAATCCGTGTCCTG  CTGGATAACCAGACTG  TGACATTTCAGCCTGACCATGAAGACGGCGGAGGCCAGGAGAC  GTTCAACGCCACCGGAG  TCCTCCTGAGCCGCAACGGCTCTGAGGTCTCGGCCAGCTTCGAC  GGCTGGGCCACCGTCT CGGTGATCGCGCTCTCCAACATCCTCCACGCCTCCGCCAGCCTC  CCGCCCGAGTACCAGA  ACCGCACGGAGGGGCTCCTGGGGGTCTGGAATAACAATCCAGA  GGACGACTTCAGGATGC  CCAATGGCTCCACCATTCCCCCAGGGAGCCCTGAGGAGATGCTT  TTCCACTTTGGAATGA  CCTGGCAGATCAACGGGACAGGCCTCCTTGGCAAGAGGAATGA  CCAGCTGCCTTCCAACT  TCACCCCTGTTTTCTACTCACAACTGCAAAAAAACAGCTCCTGG  GCTGAACATTTGATCT  CCAACTGTGACGGAGATAGCTCATGCATCTATGACACCCTGGCC  CTGCGCAACGCAAGCA  TCGGACTTCACACGAGGGAAGTCAGTAAAAACTACGAGCAGGC  GAACGCCACCCTCAATC  AGTACCCGCCCTCCATCAATGGTGGTCGTGTGATTGAAGCCTAC  AAGGGGCAGACCACGC  TGATTCAGTACACCAGCAATGCTGAGGATGCCAACTTCACGCTC  AGAGACAGCTGCACCG  ACTTGGAGCTCTTTGAGAATGGGACGTTGCTGTGGACACCCAAG  TCGCTGGAGCCATTCA  CTCTGGAGATTCTAGCAAGAAGTGCCAAGATTGGCTTGGCATCT  GCACTCCAGCCCAGGA  CTGTGGTCTGCCATTGCAATGCAGAGAGCCAGTGTTTGTACAATC  AGACCAGCAGGGTGG  GCAACTCCTCCCTGGAGGTGGCTGGCTGCAAGTGTGACGGGGG  CACCTTCGGCCGCTACT  GCGAGGGCTCCGAGGATGCCTGTGAGGAGCCGTGCTTCCCGAG  TGTCCACTGCGTTCCTG  GGAAGGGCTGCGAGGCCTGCCCTCCAAACCTGACTGGGGATGG  GCGGCACTGTGCGGCTC  TGGGGAGCTCTTTCCTGTGTCAGAACCAGTCCTGCCCTGTGAAT  TACTGCTACAATCAAG  GCCACTGCTACATCTCCCAGACTCTGGGCTGTCAGCCCATGTGC  ACCTGCCCCCCAGCCT  TCACTGACAGCCGCTGCTTCCTGGCTGGGAACAACTTCAGTCCA  ACTGTCAACCTAGAAC  TTCCCTTAAGAGTCATCCAGCTCTTGCTCAGTGAAGAGGAAAAT  GCCTCCATGGCAGAAG  TCAACGCCTCGGTGGCATACAGACTGGGGACCCTGGACATGCG  GGCCTTTCTCCGCAACA  GCCAAGTGGAACGAATCGATTCTGCAGCACCGGCCTCGGGAAG  CCCCATCCAACACTGGA  TGGTCATCTCGGAGTTCCAGTACCGCCCTCGGGGCCCGGTCATT  GACTTCCTGAACAACC  AGCTGCTGGCCGCGGTGGTGGAGGCGTTCTTATACCACGTTCCA  CGGAGGAGTGAGGAGC  CCAGGAACGACGTGGTCTTCCAGCCCATCTCCGGGGAAGACGT  GCGCGATGTGACAGCCC  TGAACGTGAGCACGCTGAAGGCTTACTTCAGATGCGATGGCTAC  AAGGGCTACGACCTGG  TCTACAGCCCCCAGAGCGGCTTCACCTGCGTGTCCCCGTGCAGT  AGGGGCTACTGTGACC  ATGGAGGCCAGTGCCAGCACCTGCCCAGTGGGCCCCGCTGCAG  CTGTGTGTCCTTCTCCA  TCTACACGGCCTGGGGCGAGCACTGTGAGCACCTGAGCATGAA  ACTCGACGCGTTCTTCG  GCATCTTCTTTGGGGCCCTGGGCGGCCTCTTGCTGCTGGGGGTC  GGGACGTTCGTGGTCC  TGCGCTTCTGGGGTTGCTCCGGGGCCAGGTTCTCCTATTTCCTG  AACTCAGCTGAGGCCT  TGCCTTAGGCTAGCCTGCAGGGATCCAATGTAACTGTATTCAGC  GATGACGAAATTCTTA  GCTATTGTAATACTCTAGAGGATCTTTGTGAAGGAACCTTACTTC  TGTGGTGTGACATAA  TTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATA  AAATTTTTAAGTGTA   TAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTC  CAACCTATGGAACT  GATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACC  TGTTTTGCTCAGAAGAA  ATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAACATTCT  ACTCCTCCAAAAAAG  AAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGC  TAAGTTTTTTGAGTCAT  GCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACAC  CACAAAGGAAAAAGCT  GCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTAACCTT  TATAAGTAGGCATAAC  AGTTATAATCATAACATACTGTTTTTTCTTACTCCACACAGGCAT  AGAGTGTCTGCTATT  AATAACTATGCTCAAAAATTGTGTACCTTTAGCTTTTTAATTTGT  AAAGGGGTTAATAAG  GAATATTTGATGTATAGTGCCTTGACTAGAGATCATAATCAGCCATA  CCACATTTGTAGA  GGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACC  TGAAACATAAAATGAA  TGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTAC  AAATAAAGCAATAG  CATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAG  TTGTGGTTTGTCCAA  ACTCATCAATGTATCTTATCATGTCTGCGGCTCTAGAGCTGCATT  AATGAATCGGCCAAC  GCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCC  TCGCTCACTGACTCGC  TGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCA  AAGGCGGTAATACGGT  TATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGC  AAAAGGCCAGCAAAAGG  CCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG  CTCCGCCCCCCTGACG  AGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCC  GACAGGACTATAAAGAT  ACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTT  CCGACCCTGCCGCTTA  CCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTT  TCTCATAGCTCACGCT  GTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGC  TGTGTGCACGAACCCC  CCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTT  GAGTCCAACCCGGTAA  GACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGAT  TAGCAGAGCGAGGTATG  TAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGC  TACACTAGAAGAACAG  TATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAA  AGAGTTGGTAGCTCTT  GATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTT  TGCAAGCAGCAGATTA  CGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCT  ACGGGGTCTGACGCTC  AGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTA  TCAAAAAGGATCTTCA  CCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAA  GTATATATGAGTAAA  CTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATC  TCAGCGATCTGTCTAT  TTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTA  CGATACGGGAGGGCT  TACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGC  TCACCGGCTCCAGATT  TATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAG  TGGTCCTGCAACTTTAT CCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAA  GTAGTTCGCCAGTTA  ATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG  TCACGCTCGTCGTTTG  GTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTT  ACATGATCCCCCATGT  TGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTC  AGAAGTAAGTTGGCCG  CAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTA  CTGTCATGCCATCCG  TAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTC  TGAGAATAGTGTATGC  GGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACC  GCGCCACATAGCAGAA  CTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAA  CTCTCAAGGATCTTAC  CGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAA  CTGATCTTCAGCATCTT  TTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCA  AAATGCCGCAAAAAAGG  GAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTT  TTTCAATATTATTGAA GCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAAT GTATTTAGAAAAATA 
